FON-2021-1486 Infographic.jpg (4.8 MB)

Infographic – STARBOARD: encorafenib + binimetinib + pembrolizumab for 1st-line metastatic/unresectable BRAF V600MT melanoma

figure

posted on 2022-03-11, 08:38 authored by Figshare Future Science GroupFigshare Future Science Group, Chizoba Nwankwo, Ruchit Shah, Anuj Shah, Shelby Corman, Nehemiah Kebede

Infographic: Design of the STARBOARD trial

Funding

Pfizer

History

Usage metrics

Read the peer-reviewed publication

STARBOARD: encorafenib + binimetinib + pembrolizumab for 1st-line metastatic/unresectable BRAF V600MT melanoma

Future Oncology

Categories

Keywords

advanced melanoma encorafenib binimetinib pembrolizumab BRAF V600 mutations immunotherapy targeted therapy triplet combination therapy Cancer Therapy (excl. Chemotherapy and Radiation Therapy)Solid Tumours

Licence

CC BY-NC-ND 4.0

Exports